Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Cameron

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
NPJ Vaccines|June 14, 2024
Association between antibody responses post-vaccination and severe COVID-19 outcomes in ScotlandCalum Macdonald, Norah Palmateer, Andrew McAuley, et al.
The Journal of Infectious Diseases|February 15, 2008
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunityMartin C J Maiden, Ana Belén Ibarz-Pavón, Rachel Urwin, et al.
The Journal of Infectious Diseases|September 2, 2011
Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementationAna Belén Ibarz-Pavón, Jenny Maclennan, Nicholas J Andrews, et al.
Wellcome Open Research|December 17, 2019
ActEarly: a City Collaboratory approach to early promotion of good health and wellbeingJohn Wright, Andrew Hayward, Jane West, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programmeJeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
NPJ Vaccines|June 14, 2024
Association between antibody responses post-vaccination and severe COVID-19 outcomes in ScotlandCalum Macdonald, Norah Palmateer, Andrew McAuley, et al.
The Journal of Infectious Diseases|February 15, 2008
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunityMartin C J Maiden, Ana Belén Ibarz-Pavón, Rachel Urwin, et al.
The Journal of Infectious Diseases|September 2, 2011
Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementationAna Belén Ibarz-Pavón, Jenny Maclennan, Nicholas J Andrews, et al.
Wellcome Open Research|December 17, 2019
ActEarly: a City Collaboratory approach to early promotion of good health and wellbeingJohn Wright, Andrew Hayward, Jane West, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 15, 2022
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programmeJeremy P Carr, Jenny M MacLennan, Emma Plested, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Pageof 8